Quest Diagnostics to Provide Diagnostic Testing Services for the Women of Ireland through Ireland's First Nationwide Cervical-Cancer Screening Program

... MADISON N.J. June 20 /- Women in Ireland ... Cervical cancer is a terrible disease that often strikes when a woman...Quest Diagnostics' relationship with the medical community of Ireland...Under the cytology-screening program Quest Diag...

MADISON, N.J., June 20 /PRNewswire-FirstCall/ -- Women in Ireland will
soon be able to take advantage of diagnostic testing services provided by
Quest Diagnostics Incorporated (NYSE: DGX), the world's leader in
cervical-cancer screening services. Through a contract with the Irish
National Cancer Screening Service (NCSS), Quest Diagnostics will provide
quality-assured screening services intended to improve medical outcomes and
reduce anxiety wait time for women ages 25 to 60 who participate in
Ireland's first nationwide cytology-screening program.

"Cervical cancer is a terrible disease that often strikes when a woman
is in the prime of her life," said Ronald Kennedy, M.D., Corporate Medical
Director, Quality Assurance in Anatomic Pathology, Quest Diagnostics. "Our
goal for this historic cytology-screening program is to ensure that Irish
women experience the highest quality of testing and service excellence,
with the goal of minimizing the incidence of cervical cancer. Our
commitment to women's health, along with our industry leading
quality-assurance practices, makes us imminently qualified to deliver the
superior testing services that Irish women deserve."

Quest Diagnostics' relationship with the medical community of Ireland
began in 2006, when the Health Service Executive (HSE), the national health
administrator for Ireland, engaged the services of Quest Diagnostics to
help reduce a critical backlog of Pap-based cervical-cancer screening
tests, also known as "Pap smears," that required screening. Since early
2007, Quest Diagnostics has performed approximately 50,000 Pap smears in
connection with this continuing project, helping to improve the delivery of
timely results.

Under the cytology-screening program, Quest Diagnostics will perform
testing on approximately 300,000 Pap smears annually at two accredited,
full-service laboratories in the U.S. The company operates approximately 30
accredited full-service laboratories in the U.S. that could provide backup
capabilities if required. In addition, Quest Diagnostics will provide
general practitioners and consultant colposcopists in Ireland with a
toll-free phone number to consult with Quest Diagnostics' medical experts
about a patient's test results.

"We applaud the NCSS for its commitment to developing a nationwide
program designed to improve the health of women through regular
cervical-cancer screening," said Kenneth R. Finnegan, Vice President,
International, Quest Diagnostics. "We look forward to working with the NCSS
and the entire medical community of Ireland to deliver world-class
diagnostic services that enhance the health of Irish women."

Quest Diagnostics is a leading provider of cervical-cancer
diagnostic-testing services, performing approximately 13 million Pap smears
in 2007. Through the cytology-screening program, women in Ireland will
benefit from services provided by a company that has adopted rigorous
standards and training programs for cytotechnologists and pathologists who
screen and review Pap smears. Quest Diagnostics requires its
cytotechnologists and pathologists to successfully perform a Pap-based
screening test prior to being considered for employment. In addition, the
company requires that its cytotechnologists register with the American
Society for Clinical Pathology (ASCP) as well as obtain accredited
continuing education. The company also provides daily conferences using a
multi-headed microscope to train its pathologists and cytotechnologists to
identify unusual characteristics from specimens taken from its sizeable
test volume.

The company's laboratories are accredited by the College of American
Pathologists (CAP), which operates accreditation programs that align with
international standards. Quest Diagnostics was the first diagnostic testing
company to employ the principles of Six Sigma in its laboratories to
promote operating and service quality. In addition, the company's medical
and scientific staff, consisting of 900 individuals with medical degrees or
Ph.D.'s, is the largest in the diagnostic testing industry.

As the world's leading provider of diagnostic testing services, Quest
Diagnostics touches the lives of patients more than 145 million times
annually. In 2008, the company was the only diagnostic testing company to
be ranked among FORTUNE magazine's list of "America's Most Admired
Companies."

About Cervical Cancer

Cervical cancer is the third leading cause of cancer death in women
worldwide, claiming an estimated 300,000 lives in 2007. Comprehensive
Pap-based screening programs could help prevent up to 80 percent of
cervical cancer cases.(1) In 2004, 200 women were diagnosed with cervical
cancer in Ireland, and more than 90 women died of the disease.(2,1)

About Quest Diagnostics

Quest Diagnostics Incorporated (NYSE: DGX) is the leading provider of
diagnostic testing, information and services that patients and doctors need
to make better healthcare decisions. The company offers the broadest access
to diagnostic testing services through its national network of laboratories
and patient service centers, and provides interpretive consultation through
its extensive medical and scientific staff. Quest Diagnostics is a pioneer
in developing innovative new diagnostic tests and advanced healthcare
information technology solutions that help improve patient care. Additional
information is available http://www.questdiagnostics.com .

(Date:12/8/2016)... ... December 08, 2016 , ... The Florida ... Undersea and Hyperbaric Medical Society (UHMS), the leading authority in hyperbaric medicine. This ... Only a few hospitals and facilities have earned this distinction. This is the ...

(Date:12/8/2016)... , ... December 08, 2016 , ... ... Chester County, a Property owned by an affiliate of Seavest, has won a ... Penn Medicine Southern Chester County ambulatory care center (ACC) was named “Best New ...

(Date:12/8/2016)... ... 08, 2016 , ... CURE Media Group, the nation’s leading digital and print ... Upstage Lung Cancer in efforts to combat lung cancer, announced CURE Media Group President ... “CURE Media Group is honored to team up with Upstage Lung Cancer in order ...

(Date:12/8/2016)... 8, 2016 Research and Markets has announced ... Trends - Adhesion Type, Application, Usability - Forecast to 2025" ... , ... Market is poised to grow at a CAGR of around 3.2% ... market is witnessing include advancements in extracellular microelectrode arrays and intracellular ...

(Date:12/8/2016)... TriNetX , the health research network, ... signed a membership agreement to join the network ... cures. The TriNetX network is comprised ... globally, biopharmaceutical companies and contract research organizations (CROs) ... site selection, patient recruitment, and collaborative research across ...

(Date:12/8/2016)... , Dec. 8, 2016 Pennsylvania Physician General ... Drug and Alcohol Programs Gary Tennis ... medications, known as benzodiazepines, developed with the help ... are medications that are frequently prescribed for anxiety ... are used with opioid pain medications, benzodiazepines pose ...